183 related articles for article (PubMed ID: 35071007)
61. Evaluation of an [(18)F]AlF-NOTA Analog of Exendin-4 for Imaging of GLP-1 Receptor in Insulinoma.
Kiesewetter DO; Guo N; Guo J; Gao H; Zhu L; Ma Y; Niu G; Chen X
Theranostics; 2012; 2(10):999-1009. PubMed ID: 23139727
[TBL] [Abstract][Full Text] [Related]
62.
Wang H; Zhu W; Ren S; Kong Y; Huang Q; Zhao J; Guan Y; Jia H; Chen J; Lu L; Xie F; Qin L
Front Oncol; 2021; 11():693640. PubMed ID: 34249748
[TBL] [Abstract][Full Text] [Related]
63. Biodistribution, pharmacokinetics, dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Tripathi M; ArunRaj ST; Sarswat S; Bal C
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1915-1931. PubMed ID: 33244617
[TBL] [Abstract][Full Text] [Related]
64. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
Loktev A; Lindner T; Burger EM; Altmann A; Giesel F; Kratochwil C; Debus J; Marmé F; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2019 Oct; 60(10):1421-1429. PubMed ID: 30850501
[TBL] [Abstract][Full Text] [Related]
65. [
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
[TBL] [Abstract][Full Text] [Related]
66. Synthesis and Evaluation of [
Zhang X; Choi JY; Lee KH; Choe YS
Mol Pharm; 2023 Dec; 20(12):6441-6450. PubMed ID: 37968928
[TBL] [Abstract][Full Text] [Related]
67. Comparison of three dimeric 18F-AlF-NOTA-RGD tracers.
Guo J; Lang L; Hu S; Guo N; Zhu L; Sun Z; Ma Y; Kiesewetter DO; Niu G; Xie Q; Chen X
Mol Imaging Biol; 2014 Apr; 16(2):274-83. PubMed ID: 23982795
[TBL] [Abstract][Full Text] [Related]
68. Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer.
Liermann J; Syed M; Ben-Josef E; Schubert K; Schlampp I; Sprengel SD; Ristau J; Weykamp F; Röhrich M; Koerber SA; Haberkorn U; Debus J; Herfarth K; Giesel FL; Naumann P
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672893
[TBL] [Abstract][Full Text] [Related]
69. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers.
Syed M; Flechsig P; Liermann J; Windisch P; Staudinger F; Akbaba S; Koerber SA; Freudlsperger C; Plinkert PK; Debus J; Giesel F; Haberkorn U; Adeberg S
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2836-2845. PubMed ID: 32447444
[TBL] [Abstract][Full Text] [Related]
70. Development and application of a fully automatic multi-function cassette module Mortenon M1 for radiopharmaceutical synthesis.
Cui FB; Lv X; Yan CL; Eng WS; Yu SY; Zheng QH
Ann Nucl Med; 2024 Apr; 38(4):247-263. PubMed ID: 38145430
[TBL] [Abstract][Full Text] [Related]
71. Renal Interstitial Fibrosis Detected on 18F-AlF-NOTA-FAPI-04 PET/CT in a Patient With Multiple Myeloma.
Wang H; Deng Y; He L; Deng Y; Zhang W
Clin Nucl Med; 2023 Oct; 48(10):896-898. PubMed ID: 37682606
[TBL] [Abstract][Full Text] [Related]
72. Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [
Treglia G; Muoio B; Roustaei H; Kiamanesh Z; Aryana K; Sadeghi R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681850
[TBL] [Abstract][Full Text] [Related]
73. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [
Guo W; Pang Y; Yao L; Zhao L; Fan C; Ke J; Guo P; Hao B; Fu H; Xie C; Lin Q; Wu H; Sun L; Chen H
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1604-1617. PubMed ID: 33179149
[TBL] [Abstract][Full Text] [Related]
74. Impact of
Röhrich M; Naumann P; Giesel FL; Choyke PL; Staudinger F; Wefers A; Liew DP; Kratochwil C; Rathke H; Liermann J; Herfarth K; Jäger D; Debus J; Haberkorn U; Lang M; Koerber SA
J Nucl Med; 2021 Jun; 62(6):779-786. PubMed ID: 33097632
[TBL] [Abstract][Full Text] [Related]
75. Positron emission tomography and computed tomography with [
Pang Y; Zhao L; Shang Q; Meng T; Zhao L; Feng L; Wang S; Guo P; Wu X; Lin Q; Wu H; Huang W; Sun L; Chen H
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1322-1337. PubMed ID: 34651226
[TBL] [Abstract][Full Text] [Related]
76. Rational Design and Pharmacomodulation of
Chen X; Xia D; Zeng X; Meng L; Wang Y; Li H; Zhang J; Zhao Z; Zhuang R; Fang J; Zhang X; Guo Z
J Med Chem; 2024 May; 67(10):8361-8371. PubMed ID: 38726551
[TBL] [Abstract][Full Text] [Related]
77.
Zhao L; Chen S; Chen S; Pang Y; Dai Y; Hu S; Lin L; Fu L; Sun L; Wu H; Chen H; Lin Q
Radiother Oncol; 2021 May; 158():55-61. PubMed ID: 33621587
[TBL] [Abstract][Full Text] [Related]
78. Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.
Lütje S; Franssen GM; Sharkey RM; Laverman P; Rossi EA; Goldenberg DM; Oyen WJ; Boerman OC; McBride WJ
Bioconjug Chem; 2014 Feb; 25(2):335-41. PubMed ID: 24382090
[TBL] [Abstract][Full Text] [Related]
79. Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment.
Glaser M; Iveson P; Hoppmann S; Indrevoll B; Wilson A; Arukwe J; Danikas A; Bhalla R; Hiscock D
J Nucl Med; 2013 Nov; 54(11):1981-8. PubMed ID: 24115530
[TBL] [Abstract][Full Text] [Related]
80. Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging.
Xu Y; Pan D; Zhu C; Xu Q; Wang L; Chen F; Yang R; Luo S; Yang M; Yan Y
Mol Imaging Biol; 2014 Aug; 16(4):578-85. PubMed ID: 24389931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
